QGEN Qiagen
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Company profile
Ticker
QGEN
Exchange
Website
CEO
Thierry Bernard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QIAGEN NV
SEC CIK
Corporate docs
QGEN stock data
()
News
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
24 Feb 21
Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics
24 Feb 21
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
10 Feb 21
Recap: Qiagen Q4 Earnings
9 Feb 21
18 Stocks Moving In Tuesday's After-Hours Session
9 Feb 21
Press releases
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
24 Feb 21
QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO's VGX-3100 for Advanced Cervical Dysplasia
24 Feb 21
QIAGEN Expands Supervisory Board With Appointment of a New Member
22 Feb 21
QIAGEN NV to Host Earnings Call
10 Feb 21
QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021
9 Feb 21
Calendar
1 Mar 20
28 Feb 21
31 Dec 21
Institutional ownership Q4 2020
50.4% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 264 |
| Opened positions | 59 |
| Closed positions | 41 |
| Increased positions | 110 |
| Reduced positions | 59 |
13F shares |
Current |
|---|---|
| Total value | 7.36B |
| Total shares | 114.84M |
| Total puts | 500.92K |
| Total calls | 2.32M |
| Total put/call ratio | 0.2 |
Largest owners |
Shares | Value |
|---|---|---|
| Davidson Kempner Capital Management | 16.5M | $855.8M |
| Massachusetts Financial Services | 11.78M | $622.73M |
| Vanguard | 7.44M | $393.27M |
| FIL | 5.9M | $304.29M |
| BLK Blackrock | 4.7M | $248.26M |
| Millennium Management | 4.28M | $226.13M |
| Wellington Management | 4.21M | $219.04M |
| DB Deutsche Bank AG - Registered Shares | 4.19M | $221.65M |
| Amundi Pioneer Asset Management | 3.44M | $181.79M |
| Farallon Capital Management | 3.26M | $172.12M |
Financial report summary
?Competition
Guided Therapeutics • Luminex • Biocept • Exact Sciences • Rosetta Genomics • Veracyte • Nanostring • GenMark Diagnostics • Great Basin Scientific • Co-DiagnosticsContent analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
agile, alphanumeric, AMG, Amgen, array, Baar, Bernard, bore, catalysation, CDLT, cervix, CGR, channel, clarity, codified, Cohn, compromise, concept, conclusion, Concord, configured, constant, criterion, cycle, Daktari, departure, descriptor, dissimilar, Dubai, dx, Editorial, eruption, Eurozone, Evotec, fell, FGFR, fifty, flat, flu, format, formatted, fruit, gap, GDF, gel, Glovsky, Heilpflanzenwohl, HepatoChem, hindsight, hub, hybridization, Illumina, implicit, impractical, incidence, Inline, Inovio, inquired, inquiring, intraperiod, Janssen, kinase, LabCorp, lessee, lessor, LLP, Mettmann, mid, Mintz, MiSeq, NaN, NCCN, NextSeq, NSE, Oncimmune, OneMed, outbreak, outweighed, PLA, plasma, Po, Popeo, Predefined, prioritize, prioritized, QBS, QIAcuity, Quanta, Quest, reoriented, resigned, resume, ROU, secondary, shift, shifted, shifting, solving, standby, superseded, supposed, Syrian, Taal, Tellacq, Thierry, Tiangen, toolbox, tough, transcription, TVM, underpayment, undiscounted, unwanted, urothelial, volcano, Wellington, XBRL
Removed:
acceleration, accomplishment, AdnaTest, AdvaMedDx, advocacy, ALDA, America, AOCI, automate, bacteria, Basel, batch, benchtop, biomedical, bottleneck, box, BRAF, buyout, Centeon, centralization, chairwoman, characterizing, Chicago, circulating, clause, cleanup, closed, closure, commencing, Computerland, connected, connectivity, Connought, constituting, CPI, cycler, decipher, dedicated, deduct, Deferral, delivering, Dept, descriptive, discovered, disseminate, disseminating, dramatic, DRG, eliminating, enrichment, escalating, everyday, exceeded, Exiqon, explore, exponentially, extending, extinguishment, fellow, flagship, frozen, furniture, FY, Gallen, GeneRead, Graduate, Greene, Halpert, handle, hereditary, hereto, hiring, Hombrechtikon, HSE, huge, influencing, ipsogen, isolation, Karobath, Lieberman, LNA, loading, Locked, Manfred, microbial, microbiome, mine, missing, myeloproliferative, negligible, notion, overseen, participated, partnered, Pasteur, pharmacogenomic, portal, postdoctoral, Poulenc, predominance, prenatal, prepayment, pretax, Prof, prostate, provisional, PS, Psychiatry, QFT, QIAact, quantifiable, random, ratio, realignment, reallocation, redemption, Regeneron, relieve, relocation, Removal, renewal, Rent, rental, revolution, Rhone, richest, robustly, rollout, Rorer, rose, rotary, RPR, Sandoz, scalable, seamlessly, securitization, setup, show, showed, slightly, Society, soil, stand, study, tenor, Triangle, Trustee, turning, varying, vast, Vedbaek, versatile, Veteran, Vienna, virtually, visualize, Waltham, wave, web, Workbench
Financial reports
20-F
2019 FY
Annual report (foreign)
1 Mar 20
20-F
2018 FY
Annual report (foreign)
5 Mar 19
20-F
2017 FY
Annual report (foreign)
5 Mar 18
20-F
2016 FY
Annual report (foreign)
5 Mar 17
20-F
2015 FY
Annual report (foreign)
28 Feb 16
20-F
2014 FY
Annual report (foreign)
1 Mar 15
20-F
2013 FY
Annual report (foreign)
2 Mar 14
20-F
2012 FY
Annual report (foreign)
3 Mar 13
20-F
2011 FY
Annual report (foreign)
26 Mar 12
20-F
2010 FY
Annual report (foreign)
20 Mar 11
Current reports
6-K
Current report (foreign)
24 Feb 21
6-K
Current report (foreign)
9 Feb 21
6-K
Current report (foreign)
8 Jan 21
6-K
Current report (foreign)
18 Dec 20
6-K
Current report (foreign)
17 Dec 20
6-K
Current report (foreign)
10 Dec 20
6-K
Current report (foreign)
8 Dec 20
6-K
Current report (foreign)
12 Nov 20
6-K
Current report (foreign)
1 Nov 20
6-K
Current report (foreign)
27 Oct 20
Registration and prospectus
SC 14D9/A
Tender offer solicitation (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
11 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
10 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
7 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
6 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
5 Aug 20
SC 14D9/A
Tender offer solicitation (amended)
4 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
4 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
3 Aug 20
Proxies
No filings
Other
SD
Conflict minerals disclosure
29 Mar 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
1 Mar 20
UPLOAD
Letter from SEC
1 Oct 19
CORRESP
Correspondence with SEC
24 Sep 19
UPLOAD
Letter from SEC
15 Sep 19
SD
Conflict minerals disclosure
7 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 19
SD
Conflict minerals disclosure
16 May 18
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 18
SD
Conflict minerals disclosure
23 Apr 17
Ownership
SC 13G/A
QIAGEN / MASSACHUSETTS FINANCIAL SERVICES ownership change
11 Feb 21
SC 13G/A
QIAGEN / WELLINGTON MANAGEMENT ownership change
3 Feb 21
SC 13G/A
QIAGEN / BlackRock ownership change
26 Jan 21
SC 13D/A
QIAGEN / DAVIDSON KEMPNER PARTNERS ownership change
22 Jan 21
SC 13D
QIAGEN / DAVIDSON KEMPNER PARTNERS ownership change
3 Aug 20
SC 13G/A
Qiagen NV
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
3 Feb 20
SC 13G
Beneficial ownership report
28 Jan 20
SC 13G/A
Beneficial ownership report (amended)
7 Jun 19